SURF - サ―フェイス・オンコロジ― （Surface Oncology Inc.）

Surface Oncology press release (SURF): Q4 GAAP EPS of -$0.35 misses by $0.03.As of December 31, 2022, cash, cash equivalents and marketable securities were $124.8 million, compared…

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Blustering Stocks Grabbing Investor’s Attention: Science 37 Holdings, Inc. (NASDAQ:SNCE), Surface Oncology, Inc. (NASDAQ:SURF) appeared first on Stocks Equity .

In the last trading session, 0.14 million Surface Oncology Inc. (NASDAQ:SURF) shares changed hands as the company’s beta touched 1.64. With the company’s per share price at $0.79 changed hands at -$0.01 or -0.50% during last session, the market valuation stood at $46.86M. SURF’s last price was a discount, traded about -370.89% off its 52-week … Surface Oncology Inc. (NASDAQ: SURF) Is Under Pressure Due To Weak Fundamental Momentum. Read More »

GSK plc found using ticker (GSK) have now 4 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 63.75 and 36.2 calculating the mean target price we have 44.29. Now with the previous closing price of 35.12 this now indicates there is a potential upside of 26.1%. The 50 day moving average now sits at 35 and the 200 moving average now moves to 37.32. The market capitalisation for the company is $72,181m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $91,028m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

https://www.investing.com/news/pro/surface-oncology-pt-lowered-to-3-at-wedbush-432SI-2930025

Surface Oncology (SURF) is laying off about 20% of its employees and pausing developing of SRF617, a phase 2 candidate targeting CD39 for solid tumors.The company is focusing resources…

A share of Surface Oncology Inc. (NASDAQ:SURF) closed at $1.35 per share on Tuesday, up from $1.24 day before. While Surface Oncology Inc. has overperformed by 8.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SURF fell by -82.05%, with highs and lows ranging from $7.97 […]

Surface Oncology (NASDAQ: SURF ) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:22 AM. Here''s what investors need to know about the announcement. Earnings Surface Oncology beat estimated earnings by 17.02%, reporting an EPS of $-0.39 … Full story available on Benzinga.com

– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –

GSK plc with ticker code (GSK) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 63.75 and 36 calculating the average target price we see 54.29. Now with the previous closing price of 28.82 this now indicates there is a potential upside of 88.4%. There is a 50 day moving average of 35.7 and the 200 day MA is 41.68. The company has a market capitalisation of $57,907m. Visit the company website at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $109,083m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

In last trading session, Surface Oncology Inc. (NASDAQ:SURF) saw 0.47 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $1.10 trading at $0.05 or 4.27% at ring of the bell on the day assigns it a market valuation of $68.53M. That closing price of SURF’s stock is … Surface Oncology Inc. (NASDAQ:SURF) Rises 4.27%, But An Additional Surge May Follow. Read More »

GSK plc with ticker code (GSK) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 63.75 and 36 with a mean TP of 54.29. Given that the stocks previous close was at 32.45 this now indicates there is a potential upside of 67.3%. The 50 day moving average now sits at 38.06 while the 200 day moving average is 42.24. The company has a market capitalisation of $65,098m. Find out more information at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $108,912m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.

GSK plc found using ticker (GSK) have now 3 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 63.75 and 36 with the average target price sitting at 54.29. Given that the stocks previous close was at 31.85 this is indicating there is a potential upside of 70.5%. The day 50 moving average is 39 while the 200 day moving average is 42.44. The company has a market capitalisation of $64,948m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $110,707m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.